0001493152-22-035087.txt : 20221209 0001493152-22-035087.hdr.sgml : 20221209 20221209201941 ACCESSION NUMBER: 0001493152-22-035087 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221202 FILED AS OF DATE: 20221209 DATE AS OF CHANGE: 20221209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Riggs Josh CENTRAL INDEX KEY: 0001956391 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 221455985 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oncocyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-409-7600 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20200213 FORMER COMPANY: FORMER CONFORMED NAME: Oncocyte Corp DATE OF NAME CHANGE: 20200205 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20150513 3 1 ownership.xml X0206 3 2022-12-02 0 0001642380 Oncocyte Corp OCX 0001956391 Riggs Josh 15 CUSHING IRVINE CA 92618 0 1 0 0 Interim CEO Common Stock, no par value 2308 D Option to Purchase Common Stock 1.33 2030-07-22 Common Stock 125000 D Option to Purchase Common Stock 5.34 2031-02-25 Common Stock 50012 D Option to Purchase Common Stock 1.39 2032-03-24 Common Stock 30000 D Option to Purchase Common Stock 1.17 2032-05-03 Common Stock 10000 D Option to Purchase Common Stock 0.4644 2023-12-07 2032-12-07 Common Stock 250000 D The Restricted Stock Units vested on May 22, 2021. 25% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to Reporting Person's continued employment with Issuer on the applicable vesting dates. 100% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant. /s/ Josh Riggs 2022-12-09